Entity Central Index Key Amortized losses reacquired debt noncurrent. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Shell Company Entity Shell Company Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, Address Line Three Entity Address Address Line3 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Restricted cash Restricted Cash Short-term investments Short Term Investments Short-term deposits Deposits Assets Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Right-of-use asset, net Operating Lease Right Of Use Asset Other assets Other Assets Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses and other current liabilities Accrued Liabilities And Other Liabilities Current portion of term loan Loans Payable Current Current portion of right-of-use liability Operating Lease Liability Current Derivative liability Derivative Liabilities Current Total current liabilities Liabilities Current Long-term liabilities: Liabilities Noncurrent [Abstract] Right-of-use liability, less current portion Operating Lease Liability Noncurrent Term loan, less current portion Long Term Loans Payable Total long-term liabilities Liabilities Noncurrent Total liabilities Liabilities Commitment and contingencies (Note 13) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2022 and December 31, 2021 Preferred Stock Value Common stock, $0.0001 par value, 100,000,000 shares authorized; 55,030,890 and 54,983,105 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive (income) loss Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Revenue: Revenues [Abstract] Total revenues Revenue From Contract With Customer Excluding Assessed Tax Type of revenue [extensible list] Type Of Revenue Extensible List Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other expense, net: Nonoperating Income Expense [Abstract] Interest expense Interest Expense Interest income Investment Income Interest Other income (expense) Other Nonoperating Income Expense Total other expense, net Nonoperating Income Expense Net loss Net Income Loss Other comprehensive income: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized (loss) gain on marketable securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Net loss attributable to common stockholders Net Income Loss Available To Common Stockholders Basic Net loss per share attributable to common stockholders—basic and diluted Earnings Per Share Basic And Diluted Weighted-average number of common shares used to compute net loss per share attributable to common stockholders —basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Depreciation and related adjustment. Non-cash operating lease expense. Statement Of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash from operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation And Related Adjustment Amortization and accretion of investments Accretion Amortization Of Discounts And Premiums Investments Non-cash operating lease expense Noncash Operating Lease Expense Non-cash interest expense Paid In Kind Interest Changes in fair value of derivate liability Derivative Gain Loss On Derivative Net Stock-based compensation Share Based Compensation Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Deferred revenue Increase Decrease In Contract With Customer Liability Accrued expenses and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of short-term investments Payments To Acquire Short Term Investments Proceeds from sales and maturities of short-term investments Proceeds From Sale And Maturity Of Available For Sale Securities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from Employee Stock Purchase Plan Proceeds From Stock Plans Proceeds from stock option exercises Proceeds From Stock Options Exercised Net cash provided by financing activities Net Cash Provided By Used In Financing Activities NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CASH, CASH EQUIVALENTS AND RESTRICTED CASH—beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CASH, CASH EQUIVALENTS AND RESTRICTED CASH —end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Business Nature Of Operations Accounting Policies [Abstract] Basis of Presentation Business Description And Basis Of Presentation [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Collaborative research and license agreements. Research And Development [Abstract] Collaborative Research and License Agreements Collaborative Research And License Agreements [Text Block] Earnings Per Share [Abstract] Net Loss per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Significant agreements disclosure. Equity [Abstract] Significant Agreements Significant Agreements Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Measurement Inputs Disclosure [Text Block] Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Payables And Accruals [Abstract] Accrued Expenses and Other Current Liabilities Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Debt Disclosure [Abstract] Loan Payable Debt Disclosure [Text Block] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Disclosure of accounting policy for Significant risks and uncertainties. Significant Risks and Uncertainties Significant Risks And Uncertainties Policy [Text Block] New Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Summary of Fair Value Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Available-for-Sale Securities Debt Securities Available For Sale Table [Text Block] Schedule of Prepaid Expenses and Other Current Assets Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Compensation Expense by Type of Award Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Summary of Restricted Stock Units Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Summary of Maturities of Principal Obligations Under Long-term Debt Schedule Of Maturities Of Long Term Debt Table [Text Block] Summary of Changes in Stockholders' Equity Schedule Of Stockholders Equity Table [Text Block] Schedule of Common Stock Reserved for Future Issuance Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Number of operating segments Number Of Operating Segments Date of incorporation Entity Incorporation Date Of Incorporation State of incorporation Short-term deposits Development costs associated with clinical trials. Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Global and united states. Global and U.S. [Member] Global And United States [Member] Ex-U.S. Countries [Member] Non Us [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Collaboration and license agreement. Incyte Agreement [Member] Collaboration And License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Incyte corporation. Incyte Corporation [Member] Incyte Corporation [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Research And Development Arrangement Contract To Perform For Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] Development costs associated with clinical trials Development Costs Associated With Clinical Trials Potential milestone payments upon achievement of milestone. Commercialization milestones and tiered royalties. Potential milestone payments to be made Potential Milestone Payments Upon Achievement Of Milestone Commercialization milestones and tiered royalties Commercialization Milestones And Tiered Royalties Upfront payments received. Upfront payments to be returned upon termination of agreement. License agreement upfront payment received Upfront Payments Received Common stock shares purchased Stock Issued During Period Shares New Issues Purchase price per share Shares Issued Price Per Share Aggregate purchase price Proceeds From Issuance Of Common Stock Upfront payments returned upon termination of agreement Upfront Payments To Be Returned Upon Termination Of Agreement Collaboration and license agreement allocated consideration received to derivative liability. Revenue recognized upon transfer of license agreement. Common stock issued at fair value Stock Issued During Period Value New Issues Allocated consideration received to derivative liability Collaboration And License Agreement Allocated Consideration Received To Derivative Liability Revenue recognized upon transfer of license agreement Revenue Recognized Upon Transfer Of License Agreement Liability related to letter agreement. Liability related to letter agreement Liability Related To Letter Agreement Reimbursable expense due from counterparty. Collaboration expense due to counterparty. Reimbursable expense due from counterparty Reimbursable Expense Due From Counterparty Collaboration expense due to counterparty Collaboration Expense Due To Counterparty Numerator—basic and diluted: Net Income Loss [Abstract] Net loss Net loss attributable to common stockholders—basic and diluted Net loss per share attributable to common stockholders—basic and diluted Denominator—basic and diluted: Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—basic and diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Options to Purchase Common Stock [Member] Employee Stock Option [Member] Employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Non-Vested Restricted Stock Units (RSUs) [Member] Restricted Stock Units R S U [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Anti-dilutive securities excluded from computation of diluted net loss per common share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Class of warrant or right issued. Number of pre funded warrants cashless exchanged for common stock. Number of pre-funded warrants exchanged for common stock. Schedule Of Earnings Per Share Basic By Common Class [Table] Schedule Of Earnings Per Share Basic By Common Class [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Pre funded warrants. Pre Funded Warrants [Member] Pre Funded Warrants [Member] Earnings Per Share Basic [Line Items] Earnings Per Share Basic [Line Items] Warrant issued Class Of Warrant Or Right Issued Warrants Outstanding Class Of Warrant Or Right Outstanding Pre-funded warrants cashless exchange Number Of Pre Funded Warrants Cashless Exchanged For Common Stock Pre-funded warrants exchange Number Of Pre Funded Warrants Exchanged For Common Stock Aggregate potential milestone payable. License agreements expiration period. Upfront payments. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Allergan license agreement. Allergan License Agreement [Member] Allergan License Agreement [Member] Vitae Pharmaceuticals, Inc. Vitae Pharmaceuticals Inc [Member] Vitae Pharmaceuticals Inc [Member] UCB license agreement. UCB License Agreement [Member] Ucb License Agreement [Member] UCB Biopharma. UCB Biopharma [Member] U C B Biopharma [Member] Clinical trial. Clinical Trial [Member] Clinical Trial [Member] Eastern Cooperative Oncology Group. Eastern Cooperative Oncology Group [Member] Eastern Cooperative Oncology Group [Member] License agreement. License Agreement [Member] License Agreement [Member] Bayer Pharma AG . Bayer Pharma AG [Member] Bayer Pharma Ag [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Upfront milestone payable Upfront Payments Aggregate potential milestone payable Aggregate Potential Milestone Payable License expiration year License Agreements Expiration Period Research and development expense Milestone payment due. Remaining contractual obligation. Contractual obligations term. Increase decrease in contractual obligation. Accrued contractual obligation. Milestone payment payable Milestone Payment Due Increase in contractual obligation Increase Decrease In Contractual Obligation Aggregate payment obligation Contractual Obligation Remaining contractual obligation Remaining Contractual Obligation Period of contractual obligation Contractual Obligations Term Accrued contractual obligation Accrued Contractual Obligation Upfront license fees paid. Up-front license fee paid Upfront License Fees Paid Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices (Unadjusted) in Active Markets Level 1 [Member] Fair Value Inputs Level1 [Member] Significant Other Observable Inputs Level 2 [Member] Fair Value Inputs Level2 [Member] Significant Unobservable Inputs Level 3 [Member] Fair Value Inputs Level3 [Member] Measurement Basis Fair Value By Measurement Basis [Axis] Fair Value Disclosure Item Amounts [Default] Portion At Fair Value Fair Value Disclosure [Member] Fair Value Measurement Fair Value Disclosure Item Amounts [Domain] Carrying Value [Member] Carrying Reported Amount Fair Value Disclosure [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Cash and cash equivalents Cash And Cash Equivalents Fair Value Disclosure Total assets Assets Fair Value Disclosure Derivative liability Derivative Liabilities Total liabilities Liabilities Fair Value Disclosure Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value Derivative liability: Derivative Liabilities [Abstract] Beginning Balance 12/31/21 Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Change in fair value Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value Ending Balance 3/31/22 Fair value measurements. Fair Value Measurements [Table] Fair Value Measurements [Table] Fair Value Measurements [Table] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Realized gains or losses recognized on the sale or maturity of available-for-sale securities Debt Securities Available For Sale Realized Gain Loss Available For Sale Securities Fair Value Disclosure [Abstract] Available For Sale Securities Fair Value Disclosure [Abstract] Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Commercial Paper [Member] Commercial Paper Not Included With Cash And Cash Equivalents [Member] Corporate Bonds [Member] Corporate Debt Securities [Member] US Treasury [Member] U S Treasury Securities [Member] Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Fair Value Available For Sale Securities Debt Securities Reimbursable costs. Prepaid insurance Prepaid Insurance Interest receivable on investments Interest Receivable Current Reimbursable costs Reimbursable Costs Other Other Prepaid Expense Current Total prepaid expenses and other current assets Accrued clinical costs current. Accrued research and development costs other. Accrued clinical costs Accrued Clinical Costs Current Accrued compensation and related costs Employee Related Liabilities Current Accrued professional fees Accrued Professional Fees Current Accrued research and development costs - other Accrued Research And Development Costs Other Other Other Accrued Liabilities Current Total accrued expenses and other current liabilities Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand fifteen omnibus incentive plan. 2015 Plan [Member] Two Thousand Fifteen Omnibus Incentive Plan [Member] Two thousand and seven stock incentive plan. 2007 Plan [Member] Two Thousand And Seven Stock Incentive Plan [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Employees. Employees [Member] Employees [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Two thousand and nineteen performance awards. 2019 Performance Awards [Member] Two Thousand And Nineteen Performance Awards [Member] Two thousand and twenty two performance awards. 2022 Performance Awards [Member] Two Thousand And Twenty Two Performance Awards [Member] Scenario Statement Scenario [Axis] Scenario Scenario Unspecified [Domain] Scenario Forecast [Member] Scenario Forecast [Member] Two thousand seven and two thousand fifteen stock incentive plan. 2015 and 2007 [Member] Two Thousand Seven And Two Thousand Fifteen Stock Incentive Plan [Member] Restricted Stock Units [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Shares available for issuance Common Stock Capital Shares Reserved For Future Issuance Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development [Member] Research And Development Expense [Member] General and Administrative [Member] General And Administrative Expense [Member] Share based compensation expense, total Allocated Share Based Compensation Expense Share based compensation arrangement by share based payment award stock option grant date fair value. Stock option granted to certain executives and employees Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Options grant date fair value amount Share Based Compensation Arrangement By Share Based Payment Award Stock Option Grant Date Fair Value Weighted average grant date fair value of options Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Employee service share based compensation recognized stock options. Employee service share based compensation recognized stock options not met. Share-based compensation, stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Share-based compensation, stock options vested Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Share-based compensation, stock options net of cancellations Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Share-based compensation, stock options outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Share-based compensation, stock options cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Stock compensation expense Employee Service Share Based Compensation Recognized Stock Options Recognized compensation expense related to stock option not met Employee Service Share Based Compensation Recognized Stock Options Not Met Stock options exercised, shares Stock Issued During Period Shares Stock Options Exercised Unrecognized compensation expense related to stock option Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Weighted average period to recognize compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Share Based Arrangements To Obtain Goods And Services [Abstract] Number of Shares, Unvested, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Number of Shares, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Number of Shares, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Number of Shares, Forfeited Number of Shares, Unvested, Ending balance Weighted Average Grant Date Fair Value, Unvested, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Unvested, Ending balance Fair value of restricted stock units vested Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value Weighted average grant date fair value per share Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value Debt Instrument [Table] Debt Instrument [Table] Lender Name Line Of Credit Facility [Axis] Line of Credit Facility, Lender Line Of Credit Facility Lender [Domain] Hercules Capital, Inc. Hercules [Member] Hercules Capital Inc [Member] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] First amendment to loan and security agreement. First Amendment to Loan Agreement [Member] First Amendment To Loan And Security Agreement [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Term loan. Term Loan [Member] Term Loan [Member] Debt instrument tranche two Tranche 2 [Member] Debt Instrument Tranche Two [Member] Debt instrument, tranche three. Tranche 3 [Member] Debt Instrument Tranche Three [Member] Scenario one. Available through April 30, 2022 [Member] Scenario One [Member] Scenario two. Available through November 30, 2022 [Member] Scenario Two [Member] Scenario Three. Not to Draw First from Tranche 2 [Member] Scenario Three [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] Wall Street Journal Prime Rate [Member] Prime Rate [Member] Loan and security agreement. Loan Agreement [Member] Loan And Security Agreement [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Aggregate maximum borrowings Line Of Credit Facility Maximum Borrowing Capacity Line of credit facility, description Line Of Credit Facility Description Percentage of end of term charge to future draws. Percentage of prepayment premium of principal amount outstanding in first year. Percentage of prepayment premium of principal amount outstanding in second year. Percentage of prepayment premium of principal amount outstanding thereafter. Interest rate description Line Of Credit Facility Interest Rate Description Interest rate Debt Instrument Interest Rate Stated Percentage Basis spread on variable rate Debt Instrument Basis Spread On Variable Rate1 Percentage of end of term charge to future draws Percentage Of End Of Term Charge To Future Draws Percentage of prepayment premium of principal amount outstanding in first year Percentage Of Prepayment Premium Of Principal Amount Outstanding In First Year Percentage of prepayment premium of principal amount outstanding in second year Percentage Of Prepayment Premium Of Principal Amount Outstanding In Second Year Percentage of prepayment premium of principal amount outstanding thereafter prior to maturity date Percentage Of Prepayment Premium Of Principal Amount Outstanding Thereafter Line of credit facility minimum cash covenant. Additional default interest rate. Line of credit facility minimum cash covenant waived. Minimum cash covenant Line Of Credit Facility Minimum Cash Covenant Minimum cash covenant waived Line Of Credit Facility Minimum Cash Covenant Waived Default interest rate Additional Default Interest Rate Interest expense related to the loan agreement Interest Expense Debt Remainder of 2022 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year 2023 Long Term Debt Maturities Repayments Of Principal In Next Twelve Months 2024 Long Term Debt Maturities Repayments Of Principal In Year Two Total principal outstanding Debt Instrument Carrying Amount Amortized final fee Amortized Losses Reacquired Debt Noncurrent Unamortized debt issuance costs Unamortized Debt Issuance Expense Total Loans Payable Term loan, less current portion Stock issued during period value pre-funded common stock warrants from direct offering. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Other Comprehensive Income / (Loss) [Member] Accumulated Other Comprehensive Income [Member] Accumulated Deficit [Member] Retained Earnings [Member] Class of Stock [Line Items] Class Of Stock [Line Items] Beginning balance Beginning balance, Shares Shares Outstanding Stock purchase under ESPP, Shares Stock Issued During Period Shares Employee Stock Purchase Plans Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Prefunded warrant exchange, Value Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering Stock issued during period shares pre funded common stock warrants from direct offering. Proceeds from exercise of stock options, shares Stock Issued During Period Shares Pre Funded Common Stock Warrants From Direct Offering Unrealized gains on short-term investments Employee withholdings ESPP Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net Proceeds from exercise of stock options, value Stock Issued During Period Value Stock Options Exercised Proceeds from exercise of stock options, shares Ending balance Ending balance, Shares Legal Entity Legal Entity [Axis] Entity Entity [Domain] Cowen and Company LLC. Cowen and Company LLC [Member] Cowen And Company L L C [Member] Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] At the market equity offering sales agreement. At The Market Equity Offering Sales Agreement [Member] At The Market Equity Offering Sales Agreement [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Incyte collaboration agreement and share purchase agreement. Incyte Collaboration Agreement and Share Purchase Agreement [Member] Incyte Collaboration Agreement And Share Purchase Agreement [Member] Class Of Stock [Line Items] Proceeds from issuance of common stock in follow-on public stock offering, net Common stock, new shares issued Common stock reserved for future issuance